- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07948928
EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care
Evaluation of Quality Improvement Initiative to Improve GLP-1 and CGM Prescription Rates
This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them. The alerts will remind providers that a patient is eligible for a GLP-1 RA, a CGM, or both, and will help them choose the option covered by the patient's insurance. Providers in both groups will use their own clinical judgment in deciding whether to prescribe. The study will use information already recorded in patients' medical records.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Primary care providers (physicians, physician assistants and nurse practitioners) are randomized 1:1, stratified by site type (teaching vs. non-teaching), prior GLP-1 RA prescribing, and eligible-patient volume. Approximately 121 providers will be randomized. The patients they see who meet eligibility criteria during the study period are the enrolled participants and are reflected in the enrollment count. Residents and their patients are excluded. For providers in the intervention arm, the alert is an Our Practice Advisory (OPA) in Epic that fires during qualifying in-person or telehealth primary care visits. Patients eligible for both a GLP-1 RA and a CGM trigger a single combined alert; patients eligible for only one trigger only that portion of the alert. Intervention-arm providers also receive education on using the alert. Outcomes are analyzed at the patient level using only each patient's first qualifying visit. The analysis uses mixed-effects logistic regression with a random effect for provider.
Note: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined this quality improvement project does not meet the definition of human subjects research. An IRB determination letter is on file with this registration.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Shivani Agarwal, MD, MPH
- Telefonnummer: 32 844-556-6683
- E-post: shagarwa@montefiore.org
Studera Kontakt Backup
- Namn: Silvie Colman
- E-post: scolman@montefiore.org
Studieorter
-
-
New York
-
The Bronx, New York, Förenta staterna, 10467
- Rekrytering
- Montefiore Medical Center
-
Kontakt:
- Shivani Agarwal, MD, MPH
- Telefonnummer: 32 844-556-6683
- E-post: shagarwa@montefiore.org
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Meet Klompas definition of diabetes
- Has at least one primary care visit, in-person or telehealth, during the study period
- Is covered by Medicare or Medicaid
Additional inclusion criteria for the GLP-1 portion of the OPA alert:
- GLP-1 component: HbA1c ≥ 9 on most recent lab test in the past 12 months and a BMI ≥ 25) OR BMI ≥ 30, and no GLP-1 prescription in the past 12 months
Additional inclusion criteria for the CGM portion of the OPA alert:
- CGM component: Insulin prescription in the past 12 months and no CGM prescription in the past 12 months
Exclusion Criteria:
- Patients seen by residents during their first visit
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Our Practice Advisory (OPA) Alert
Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients. |
Electronic Health Record (EHR) Our Practice Advisory, a pop-up electronic notification for clinical staff available at the time of a clinical encounter in the electronic medical record, recommending the insurance-preferred GLP-1 and/or a CGM, plus education for providers on using the alerts |
|
Inget ingripande: Usual Care (UC)
Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication
Tidsram: At the first qualifying primary care visit during the study period, up to 3 months
|
The percentage of patients meeting the GLP-1 RA alert eligibility criteria who are newly prescribed a GLP-1 RA covered by their insurance, as documented in the electronic health record. GLP-1 RAs not covered by the patient's insurance are not counted. Each patient's first qualifying visit during the study period is analyzed. |
At the first qualifying primary care visit during the study period, up to 3 months
|
|
Percentage of Eligible Patients Newly Prescribed a CGM
Tidsram: At the first qualifying primary care visit during the study period, up to 3 months
|
The percentage of patients meeting the CGM alert eligibility criteria who are newly prescribed a continuous glucose monitor (CGM), as documented in the electronic health record. Each patient's first qualifying visit during the study period is analyzed. |
At the first qualifying primary care visit during the study period, up to 3 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Provider Response to the OPA alert
Tidsram: Throughout the study period, up to 3 months
|
For the OPA arm only, providers interaction with the OPA alert will be evaluated based on the percentage of time the OPA alert fired and was either: ignored, declined, and approved. The unit of analysis are patients. Each nominal categorical variable will be summarized. |
Throughout the study period, up to 3 months
|
|
Reasons for Declining the OPA alert
Tidsram: Throughout the study period, up to 3 months
|
Among alert firings declined by providers in the OPA Alert arm, the percentage for each decline reason selected in the electronic health record will be summarized. The reasons are: Defer to Next Visit; Patient Declines; Chart Review Only; Does Not Meet Criteria; Financial Limitations; Treatment Ineffective; Patient Can't Tolerate. The unit of analysis are patients. |
Throughout the study period, up to 3 months
|
|
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics
Tidsram: Throughout the study period, up to 3 months
|
Primary outcome evaluated by patient Body Mass Index (BMI) category, HbA1c category, Insulin status, Age group, Sex, and Race/Ethnicity. The unit of analysis are patients. |
Throughout the study period, up to 3 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Shivani Agarwal, MD, MPH, Montefiore Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
- Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
- Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. JAMA. 2021 Jun 8;325(22):2273-2284. doi: 10.1001/jama.2021.6530.
- Ehrhardt N, Al Zaghal E. Behavior Modification in Prediabetes and Diabetes: Potential Use of Real-Time Continuous Glucose Monitoring. J Diabetes Sci Technol. 2019 Mar;13(2):271-275. doi: 10.1177/1932296818790994. Epub 2018 Aug 1.
- Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R, Toschi E, Kollman C, Bergenstal R; DIAMOND Study Group. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Sep 19;167(6):365-374. doi: 10.7326/M16-2855. Epub 2017 Aug 22.
- Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM; MOBILE Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 Jun 8;325(22):2262-2272. doi: 10.1001/jama.2021.7444.
- Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Fitterman N, Balzer K, Boyd C, Humphrey LL, Iorio A, Lin J, Maroto M, McLean R, Mustafa R, Tufte J. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern Med. 2018 Apr 17;168(8):569-576. doi: 10.7326/M17-0939. Epub 2018 Mar 6.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57. doi: 10.1053/j.gastro.2007.03.054.
- Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010 Dec;85(12 Suppl):S3-4. doi: 10.4065/mcp.2010.0466. Epub 2010 Nov 24. No abstract available.
- GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-234. doi: 10.1016/S0140-6736(23)01301-6. Epub 2023 Jun 22.
- Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, Yuan CS. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410. doi: 10.1136/bmj-2023-076410.
- Hemming K, Taljaard M. Key considerations for designing, conducting and analysing a cluster randomized trial. Int J Epidemiol. 2023 Oct 5;52(5):1648-1658. doi: 10.1093/ije/dyad064.
- Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
- Pilla SJ, Segal JB, Maruthur NM. Primary Care Provides the Majority of Outpatient Care for Patients with Diabetes in the US: NAMCS 2009-2015. J Gen Intern Med. 2019 Jul;34(7):1089-1091. doi: 10.1007/s11606-019-04843-9. No abstract available.
- Vigersky RA, Fish L, Hogan P, Stewart A, Kutler S, Ladenson PW, McDermott M, Hupart KH. The clinical endocrinology workforce: current status and future projections of supply and demand. J Clin Endocrinol Metab. 2014 Sep;99(9):3112-21. doi: 10.1210/jc.2014-2257. Epub 2014 Jun 18.
- American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S183-S215. doi: 10.2337/dc26-S009.
- Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. N Engl J Med. 2026 Apr 2;394(13):1313-1324. doi: 10.1056/NEJMra2500106.
- American Diabetes Association Professional Practice Committee for Diabetes*. 7. Diabetes Technology: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S150-S165. doi: 10.2337/dc26-S007.
- Nemlekar PM, Hannah KL, Green CR, Norman GJ. Association Between Adherence, A1C Improvement, and Type of Continuous Glucose Monitoring System in People with Type 1 Diabetes or Type 2 Diabetes Treated with Intensive Insulin Therapy. Diabetes Ther. 2024 Mar;15(3):639-648. doi: 10.1007/s13300-023-01529-8. Epub 2024 Jan 30.
- Porter M, Fonda S, Swigert T, Ehrhardt N. Real-Time Continuous Glucose Monitoring to Support Self-Care: Results from a Pilot Study of Patients With Type 2 Diabetes. J Diabetes Sci Technol. 2022 Mar;16(2):578-580. doi: 10.1177/19322968211053886. Epub 2021 Oct 25. No abstract available.
- Martens TW, Parkin CG. How use of continuous glucose monitoring can address therapeutic inertia in primary care. Postgrad Med. 2022 Aug;134(6):576-588. doi: 10.1080/00325481.2022.2080419. Epub 2022 May 27.
- Reaven PD, Newell M, Rivas S, Zhou X, Norman GJ, Zhou JJ. Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Diabetes Care. 2023 Apr 1;46(4):854-863. doi: 10.2337/dc22-2189.
- Ren X, Hua H, Wu Y, Zhang W, Long X, Bai Y, Cheng N. Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis. Sci Rep. 2025 Jul 6;15(1):24103. doi: 10.1038/s41598-025-09807-0.
- Qaseem A, Obley AJ, Shamliyan T, Hicks LA, Harrod CS, Crandall CJ; Clinical Guidelines Committee of the American College of Physicians; Balk EM, Cooney TG, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Miller MC, Shekelle P, Tice JA, Tufte JE, Etxeandia-Ikobaltzeta I, Yost J. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 May;177(5):658-666. doi: 10.7326/M23-2788. Epub 2024 Apr 19.
- Horwitz LI, Kuznetsova M, Jones SA. Creating a Learning Health System through Rapid-Cycle, Randomized Testing. N Engl J Med. 2019 Sep 19;381(12):1175-1179. doi: 10.1056/NEJMsb1900856. No abstract available.
- Horwitz LI, Krelle HA. Using Rapid Randomized Trials to Improve Health Care Systems. Annu Rev Public Health. 2023 Apr 3;44:445-457. doi: 10.1146/annurev-publhealth-071521-025758. Epub 2022 Nov 18.
- Pletcher MJ, Lo B, Grady D. Randomized Quality Improvement Trials: An Overview and Proposed Framework for Ethical Oversight. Ann Intern Med. 2026 Oct;179(10):1444-1452. doi: 10.7326/ANNALS-26-00221. Epub 2026 Aug 18.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Metaboliska sjukdomar
- Störningar i glukosmetabolism
- Närings- och metabola sjukdomar
- Diabetes mellitus, typ 2
- Diabetes mellitus
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Alkaloider
- Purinoner
- Puriner
- Xantiner
- Koffein
Andra studie-ID-nummer
- 2026-793
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .